Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Feb 1;79(3):462-7.
doi: 10.1002/(sici)1097-0142(19970201)79:3<462::aid-cncr6>3.0.co;2-k.

Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma

J Y Cho  1 , J H Kim, Y H Lee, K Y Chung, S K Kim, S J Gong, N C You, H C Chung, J K Roh, B S Kim
Affiliations

Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma

J Y Cho et al. Cancer. .

Abstract

Background: Mutations at codons 12, 13, and 61 of the three ras genes, H-ras, K-ras, and N-ras, convert these genes into active oncogenes. It appears that ras gene mutations can be found in a variety of tumor types. The purpose of this study was to evaluate the clinical significance of K-ras gene mutation in nonsmall cell lung carcinoma (NSCLC).

Methods: The authors analyzed 58 NSCLC patients for mutations at codons 12, 13, and 61 of the K-ras gene and correlated the findings with the tumor stage and patient survival. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and the direct nucleotide sequencing method were used to detect mutations after amplification of ras specific sequences by PCR.

Results: Fourteen mutations (24%) of ras genes were found, all at codon 12 of the K-ras gene. GGT to GAT transition was the predominant mutational pattern. There was a significant association between K-ras mutation and the tumor stage (i.e., the higher the stage, the higher the mutation rate) (P = 0.014). Using univariate analysis, the presence of K-ras mutation in paraffin embedded tissue from patients who received treatment with curative intent was associated with a shorter survival (P = 0.039). The median survival duration for patients with or without K-ras mutation was 9 and 30 months, respectively. The Cox proportional hazards model also predicted a higher risk for patients with K-ras mutations (P = 0.047).

Conclusions: K-ras mutations, present in a subset of NSCLC, are associated with tumor progression and shortened patient survival.

PubMed Disclaimer

Publication types